奥氮平治疗老年痴呆43例临床分析

目的：分析奥氮平治疗老年痴呆精神行为症状的疗效。方法：选取我院2010年12月-2012年12月间收治的86名老年痴呆患者作为研究对象,随机分为观察组与对照组,每组患者各43例。对照组采用常规药物治疗,观察组在时照组的基础上进行奥氮平治疗,治疗两个月时间后对两组患者的临床疗效进行分析对比。结果：通过两个月的治疗发现,观察组显效25例,好转13例,无效5例,有效率（显效十好转）为88．37％;对照组显效14例,好转19例,无效10例,有效率76．74％,观察组患者的疗效明显优于对照组,两组比较差异具有统计学意义（P〈0．05）。患者的兴奋或激惹和失眠不髓反应的发生率明显低于对照组（P〈0．05）。结论：奥氮平治疗老年痴呆精神行为症状具有良好的疗效,值得在临床应用上推广。     

老年痴呆精神行为症状的药物治疗(综述)

老年痴呆病程长,医疗和照料负担重,直接和间接医疗费用都很高,已成为老龄化社会的重要社会、卫生和经济负担问题。本文从老年人的药代学、药效学特点出发,结合老年痴呆精神症状的发病机制,联系精神药物的临床应用,就精神药物在痴呆的精神行为症状(BPSD)治疗中的应用原则展开讨论,使临床医师能够对如何安全有效的使用精神药物治疗BPSD有一定的认识和指导作用。     

老年痴呆的精神行为症状喹硫平治疗研究

目的:探讨喹硫平治疗老年痴呆的精神行为症状(BPSD)的疗效与血药浓度的关系。方法:将97例伴BPSD的老年痴呆患者给予喹硫平治疗8周,于用药前及用药后1周末、2周末、4周末、8周末进行TESS、NPI、血药浓度检测,以NPI减分率≥25%为标准将病例分为有效组和无效组,用SPSS统计软件对有效病例血药浓度和临床用药剂量、临床疗效及副反应之间的相关性进行spearman相关性分析,利用ROC受试者工作曲线对有效浓度阈值进行判断。结果:1喹硫平治疗8周后NPI明显降低,从第一周开始即有显著性差异;2受试者药量与血药浓度相关系数(pearson相关)为0.988,P=0.002;4~8周的相关性检验显示血药浓度与NPI减分率相关性较好;3喹硫平治疗BPSD有效血药浓度为193~204ng/ml;4各个治疗期间不良反应率相当。结论:喹硫平治疗痴呆的精神行为症状有效,且患者疗效与喹硫平的血药浓度密切相关,其推荐血药浓度为193~204ng/ml,喹硫平在合理血药浓度下治疗痴呆精神行为症状安全性较好。     

美金刚治疗老年痴呆患者伴精神行为症状的对照研究

目的评价美金刚治疗老年痴呆(AD)患者伴发精神和行为症状(BPSD)的疗效及安全性,为此类患者的治疗提供依据。方法将2015年1月至2016年5月天津市安定医院老年科收治的90例老年痴呆且伴发BPSD的患者随机分为美金刚组与奥氮平组,治疗8周。在治疗前、治疗2周末、4周末和8周末,采用痴呆病理行为评定量表(BEHAVE-AD)评定疗效,简易精神状况检查量表(MMSE)评定患者认知功能,日常生活能力量表(ADL)评定患者生活质量,不良反应症状量表(TESS)评定不良反应。用SPSS 12.0统计软件进行统计学分析,计量资料的比较采用t检验,计数资料的比较采用χ2检验。结果美金刚组在治疗后第8周末BEHAVE-AD评分[(12.67±4.46)分]较奥氮平组[(15.78±5.75)分]显著下降,差异有统计学意义(t=2.74,P0.01)。美金刚组在治疗后第8周末MMSE评分[(15.69±3.33)分]较治疗前[(13.62±4.45)分]显著升高,差异有统计学意义(t=2.42,P0.05);奥氮平组MMSE评分治疗前[(13.35±4.19)分]与治疗2周末[(13.28±3.78)分]、4周末[(13.25±3.80)分]、8周末[(13.48±3.24)分]比较,差异均无统计学意义(t值分别为0.08、0.11和0.15,P0.05);治疗第8周末,两组患者MMSE评分差异有统计学意义(t=3.05,P0.01)。与治疗前[美金刚组:(41.02±8.89)分、奥氮平组:(41.43±9.45)分]比较,两组治疗后第8周末ADL评分[美金刚组:(35.05±7.25)分、奥氮平组:(36.15±7.94)分]均显著下降,差异均有统计学意义(t值分别为3.38和2.70,P0.01);治疗第8周末,两组患者ADL评分比较,差异无统计学意义(t=0.66,P0.05)。奥氮平组便秘、头昏头晕、锥体外系反应、嗜睡、体重增加方面的不良反应发生率明显高于美金刚组,差异均有统计学意义(P0.05,P0.01)。结论美金刚能够有效改善老年痴呆患者的精神和行为症状,而且安全性较好。此外,美金刚还能够改善患者的认知功能。     

奥氮平合并度洛西汀治疗躯体化障碍对照研究

目的 探讨奥氮平合并度洛西汀治疗躯体化障碍的疗效及安全性.方法 将本院54例躯体化障碍患者按治疗方法不同分2组,研究组（28例）用奥氮平合并度洛西汀治疗;对照组（26例）单用度洛西汀治疗.两组治疗8周,采用SCL-90躯体化因子分、汉密顿抑郁量表（HAMD）、汉密顿焦虑量表（HAMA）及副反应评定量表（TESS）评定疗效和不良反应.结果 两组治疗后SCL-90躯体化因子分、HAMD、HAMA评分较治疗前低,其差异均有统计学意义（P＜0.05）,研究组治疗8周有效率（82.1％）高于对照组（50％,P ＜0.05）,治疗1周起效较对照组快,其差异有统计学意义（P＜0.05）.两组患者不良反应较轻,大部分出现在用药初期,对症治疗后不良反应减轻或消失.结论 奥氮平合并度洛西汀治疗躯体化障碍比单用度洛西汀疗效更好,起效更快,安全性.     

奥氮平治疗老年痴呆伴发精神障碍的临床应用价值研究

目的:探析老年痴呆伴发精神障碍患者应用奥氮平治疗对病情的控制作用及安全性。方法:纳入本院2019年-2020年间确诊为老年痴呆伴发精神障碍患者80例作为本次研究的分析对象,应用硬币随机分组法将患者均等分为对照组与观察组,分别应用利培酮、奥氮平治疗,探究两组老年痴呆伴发精神障碍患者临床数据比较奥氮平的应用价值。结果:医师根据患者病症下通过不同治疗方式治疗过程中可知,观察组患者在医师治疗干预下疗效方面相较于对照组患者更具优势性(P 0.05);在用药后两组患者PANSS(阳性症状和阴性症状量表)所得分数可知患者疗效情况均得到改善,在不同时间观察下可见观察组患者相较于对照组患者在数据上更具优越性(P 0.05)。结论:老年痴呆伴发精神障碍患者应用奥氮平治疗对病情不仅有着显著疗效,对患者的安全性有着可靠保障,对患者病情起到缓解作用,值得推广。     

奥氮平与利培酮治疗老年痴呆伴发精神障碍的疗效及安全性比较

目的比较奥氮平与利培酮治疗老年痴呆伴发精神障碍的疗效及安全性。方法选取我院2014年3月至2016年8月期间收治的100例老年痴呆伴发精神障碍患者,随机分为研究组与对照组,各50例。研究组采用奥氮平治疗,对照组采用利培酮治疗。分析比较两组患者的治疗效果和不良反应情况。结果治疗后,两组患者的总有效率比较差异无统计学意义(P>0.05)。研究组的阿尔茨海默行为病理评估量表(BEHAVE-AD)评分改善情况明显优于对照组(P<0.05)。研究组的不良反应发生率显著低于对照组(P<0.05)。结论应用奥氮平与利培酮治疗老年痴呆伴发精神障碍患者,均能够获得良好的疗效,但奥氮平具有更高的安全性和临床应用价值。     

氟西汀联用奥氮平治疗难治性抑郁症的疗效观察（附19例报告）

目的观察氟西汀联用奥氮平或米氮平治疗难治性抑郁症的疗激。方法将38例难治性抑郁症患者随机分2组,A组（19例）给予氟西汀、奥氮平治疗,B组（19例）采用氟西汀、米氮平治疗,2组分别用17项汉密尔顿抑郁量表（HAMD）和HAMA量表进行疗效评价,对比2组疗效。结果治疗1周后,2组HAMD总分降到（20．32±4．49）、（21．06±2．77）分,与治疗前比较差异有统计学意义。2组总疗效相近,治疗一周后HAMA因子Ⅱ和治疗六周后HAMD因子Ⅰ、Ⅲ、Ⅴ、Ⅶ、HAMA总分、HAMA因子Ⅱ,2组差异有统计学意义（P〈0．05）。结论2组药物治疗能快速有效治疗难治性抑郁症,疗效相当。偏执和消极症状明显的患者更适合A组治疗,B组更适合治疗以焦虑／躯体化症状和阻滞症状为主的患者。     

奥氮平替换其他抗精神病药治疗老年精神分裂症的疗效分析

目的：探讨使用奥氮平替换其他非典型抗精神病药物治疗老年精神分裂症的临床疗效、耐受性和安全性。方法：对60例使用其他非典型抗精神病药治疗的老年精神分裂症患者替换奥氮平治疗8w,采用PANSS、TESS作为评估工具,于换药前及换药后的第1、2、4、8w进行测评,对换药前后的疗效、耐受性和安全性进行比较。结果：有58例患者能顺利地从原来使用的药物替换了奥氮平治疗,替用奥氮平治疗8w显效率76.7%,有效率88.3%,PANSS总分和阳性症状、一般精神病性因子分在治疗2w末起均较治疗前下降显著,差异有统计学意义（P〈0.05）,阴性症状因子分治疗4w末起有显著下降,与之前治疗比较差异有统计学意义（P〈0.05）,而且随治疗时间越长下降越明显,药物的不良反应少。结论：奥氮平替换其他非典型抗精神病药物,可以提高疗效,减少副反应,显示了良好的疗效、耐受性和安全性,有较好的治疗依从性,有利于长期服药的维持治疗。     

多奈哌齐联合奥氮平对脑血管病伴精神行为症状患者精神状态与认知功能的影响

目的 探讨脑血管病伴精神行为症状患者联合使用多奈哌齐及奥氮平对精神状态与认知功能的影响。方法 选择2018年1月—2019年3月本院收治的62例脑血管病伴精神行为症状患者作为研究对象,随机分为对照组和观察组,各31例。对照组采用奥氮平片,观察组在对照组基础上采用盐酸多奈哌齐片,比较2组患者精神状态量表(MMSE)、蒙特利尔认知量表(MoCA)评分以及不良反应。结果 治疗后,与对照组相比,观察组MMSE评分(25.47±4.32)及MoCA评分(25.83±3.19)均较高,差异有统计学意义(P=0.000);2组不良反应发生率对比(9.68% vs 3.23%),差异无统计学意义(P=0.301)。结论 脑血管病伴精神行为症状患者联合应用多奈哌齐及奥氮平,可有效改善精神状态,提高认知能力,且安全性较高。     

不同药物治疗老年血管性痴呆的疗效及对生活质量的影响

目的探讨不同药物治疗老年血管性痴呆的临床疗效及对患者生活质量的影响。方法按照随机分层分组法,将本院收治的112例老年血管性痴呆患者分为观察组和对照组,对照组给予盐酸多奈哌齐。观察组在此基础上给予参芎葡糖糖注射液,观察2组治疗前后认知功能、生活能力及生活质量的变化。结果2组治疗后简易智能状态量表（MMSE）评分、日常生活能力量表（ADL）评分及生活质量SF36量表评分均优于治疗前（P〈0．05）,观察组MMSE量表评分、ADL量表评分及SF36量表评分优于对照组（P〈0．05）。观察组临床总有效率为92．1％（70／76）,对照组临床总有效率为80．4％（37／46）,2组差异有统计学意义（P〈0．05）,观察组不良反应发生率为7．9％（6／76）,对照组不良反应发生率为6．5％（3／46）,2组差异无统计学意义（P〉0．05）。结论参芎葡萄糖注射液能显著改善VD患者的认知功能和日常生活能力,在提高临床治疗效果同时,不会增加不良反应发生率,具有重要的临床应用价值,     

The use of novel antipsychotics in the older patient with neurodegenerative disorders in the long-term care setting

Treating older patients with neurodegenerative disorders involves numerous challenges. The older patient population is expected to increase appreciably in the coming years; thus, there will be increasing numbers of these individuals requiring treatment. As a result, the appropriate choice of psychopharmacologic agents becomes an important decision in treating older patients with atypical antipsychotics. The atypical antipsychotic medications are replacing the high-potency conventional antipsychotics in the long-term care setting because of the lower risks of side effects. For instance, atypical antipsychotics have lower rates of extrapyramidal side effects and tardive dyskinesia. Double-blind placebo-controlled trials examining the use of risperidone and olanzapine have been published and indicate that both agents safely and effectively reduce agitation symptoms in long-term care patients with neurodegenerative disorders. For instance, based on these studies, the doses that appear efficacious in treating behavioral agitation in dementia are 0.5 to 1.5 mg per day of risperidone and 5 to 10 mg per day of olanzapine. In addition, there are open-label studies examining the use of quetiapine, which suggest that this agent is also safe and efficacious in patients with dementia. Doses used range approximately from 25 to 350 mg per day. Very few studies are available examining the newest atypical antipsychotics, ziprasidone and aripiprazole, in patients with neurodegenerative disorders. These studies do suggest that ziprasidone and aripiprazole are worth further study in the long-term care setting.     

Safety profile assessment of risperidone and olanzapine in long-term care patients with dementia

OBJECTIVE: To assess the adverse events associated with the appropriate use of oral risperidone and oral olanzapine in long-term care patients with behavioral and psychotic disturbances associated with dementia. DESIGN: Observational analysis. SETTING: Analysis was performed at five consulting pharmacist sites across the United States. Participants were recruited at 89 skilled nursing facilities by consultant pharmacists who provided services at each site. PATIENTS: A total of 730 men and women with dementia who had been residents of a skilled nursing facility for at least 90 days were included in the study. Alzheimer's disease was the primary diagnosis in 47% of patients. INTERVENTION: Patients were treated with risperidone < or =2 mg/day or olanzapine < or =10 mg/day for at least 90 days. MEASUREMENTS: Targets for antipsychotic use included nonaggressive symptoms of psychosis and verbally and physically aggressive behaviors. The effects of risperidone and olanzapine were determined from progress notes, psychotropic monitoring forms, and physicians' order forms after 91 days of treatment. Adverse events of particular significance in the elderly population, including agitation/anxiety, laxative use, dry eyes, and falls, were collected from audited medical records. The evaluation period extended from 3 months before to 3 months after initiation of treatment with risperidone or olanzapine. RESULTS: There were 474 patients in the risperidone group and 256 patients in the olanzapine group. Mean dosages of risperidone at Days 1 and 91 (0.7 +/- 0.3 mg/day and 1.0 +/- 0.5 mg/day, respectively) and olanzapine (3.3 +/- 1.4 mg/day and 4.7 +/- 2.1 mg/day, respectively) were at least 50% lower than the maximum dosages recommended by the Center for Medicare and Medicaid Services for elderly patients with psychosis or behavioral symptoms of dementia. The need for eye lubrication was minimal in both groups and did not differ significantly between them. Anxiolytic use decreased in the risperidone group and remained constant in the olanzapine group, with no significant difference between groups. In the olanzapine and risperidone groups, the number of patients with orders for laxatives increased 10.2% and 1.8%, respectively (P = 0.003), the mean number of days of laxative administration increased 19.1% and 4.3%, respectively (P < 0.001), and the mean number of doses of laxative administered increased 14.2% and 4.1%, respectively (P = 0.001). Among patients qualifying for analysis, falls were recorded for 17.9% of patients receiving olanzapine and 6.9% receiving risperidone (P = 0.001). CONCLUSION: Among long-term care residents with dementia who received low doses of risperidone or olanzapine, the incidence of adverse events was low. When considering adverse events of particular concern in the elderly, specifically falls and laxative use, risperidone may be preferred over olanzapine in this population.     

Efficacy and adverse reactions of antipsychotics for neuropsychiatric symptoms in dementia: a systematic review

OBJECTIVE: To assess the efficacy and adverse reactions of typical and atypical antipsychotics in the treatment of neuropsychiatric symptoms in dementia, and to examine the evidence for the cerebrovascular events warning for atypical antipsychotics. DESIGN: Systematic review. METHOD: Using Medline, Cinahl, PsyclNFO, Embase and the Cochrane central register of controlled trials (1980-2005), double-blind randomized controlled trials with intention-to-treat analysis were selected, which evaluated efficacy and adverse reactions of antipsychotics in the treatment of neuropsychiatric symptoms in dementia. The studies underwent a standardised validity assessment. RESULTS: After screening 950 studies, 14 studies on the effect of haloperidol, risperidone, olanzapine, quetiapine, tiapride, loxapine and perphenazine were selected. In 7 out of 10 studies, haloperidol, risperidone and olanzapine appeared to be more effective than placebo in the treatment of aggression and psychosis. Direct comparison between typical and atypical antipsychotics revealed no statistically significant difference. The most common adverse reactions were extrapyramidal symptoms and somnolence. These adverse reactions were less frequent with low-dose risperidone than with haloperidol or olanzapine, but risperidone and olanzapine were found to be associated with a higher risk of cerebrovascular events in two studies. CONCLUSION: The efficacy of typical and atypical antipsychotics is comparable, but only low-dose risperidone seems to be associated with fewer (extrapyramidal) side effects. The adverse reactions are inadequately described in the published data and consequently the warning of an increased risk of mortality could not be confirmed.     

Dementia with Lewy bodies; 2 patients with exacerbation due to an atypical antipsychotic,but with a favorable response to the cholinesterase inhibitor rivastigmine

In two patients, men aged 80 and 75 years with cognitive deterioration, hallucinations and parkinsonism, the clinical diagnosis 'dementia with Lewy bodies' was established. Treatment with an atypical antipsychotic, risperidone and olanzapine respectively, resulted in an exacerbation of the parkinsonism. Rivastigmine evidently improved the psychosis, the anxiety and the cognitive, mood and behaviour disorders. Titrated treatment with levodopa improved the mobility without an increase of the psychosis. The treatment of dementia with Lewy bodies is complex. Levodopa can lead to an increase in visual hallucinations. Antipsychotics often cause serious side effects, such as increasing parkinsonism, sedation and cognitive deterioration. Cholinesterase inhibitors such as rivastigmine could possibly provide an alternative treatment for the neuropsychiatric symptoms.     

Outcomes and Costs of Risperidone versus Olanzapine in Patients with Chronic Schizophrenia or Schizoaffective Disorders: A Markov Model

OBJECTIVE: To compare expected outcomes and costs of care in patients with chronic schizophrenia or schizoaffective disorders who are treated with risperidone versus olanzapine. METHODS: A Markov model was developed to examine outcomes and costs of care in patients with chronic schizophrenia or schizoaffective disorders receiving risperidone or olanzapine. The time frame of interest was 1 year. The model focused particular attention on the likelihood of therapy switching and discontinuation as a result of treatment-emergent side effects, as the efficacy of these two agents is similar. Measures of interest included the incidence of relapse and selected side effects including extrapyramidal symptoms (EPS), prolactin-related disorders and diabetes, expected change in body weight, and the percentage of patients remaining on initial therapy at the end of 1 year. Costs of antipsychotic therapy and psychiatric and nonpsychiatric services also were examined. RESULTS: At 1 year, the rate of EPS was estimated to be slightly higher for risperidone, as was the incidence of symptomatic prolactin-related disorders. The expected incidence of diabetes mellitus, while low, was slightly higher for olanzapine. Approximately 25% and 4% of olanzapine and risperidone patients, respectively, were projected to experience an increase in body weight > or = 7%. The estimated percentage of patients remaining on initial therapy at the end of 1 year was higher for risperidone than olanzapine (76.9% vs. 45.6%, respectively). Expected mean total costs of care per month of therapy were $2163 for risperidone and $2316 for olanzapine. Results from sensitivity analyses suggest that the probability of therapy discontinuation following weight gain >5 kg would have to be lower than 0.1 for the number of patients remaining on therapy at the end of 1 year to be the same for risperidone and olanzapine. CONCLUSIONS: Compared with risperidone, treatment with olanzapine may result in greater increases in body weight, higher rates of therapy discontinuation, and higher costs of medical-care services.     

老年肺结核70例临床分析

目的讨论老年肺结核患者的病生理特点和治疗中常见的问题,以达到早期诊断与治疗的目的。方法采用回顾性统计分析的方法,对70例60岁以上的老年患者的临床表现、并发症、治疗方法及效果进行统计分析。结果具有典型临床症状的患者占50%,存在并发症的占25.7%,70例患者经治疗后治愈的64例(91.43%),病变吸收好转2例(2.86%),合并肺癌死亡4例(5.71%)。结论老年患者由于特殊的生理特点往往具有临床症状不典型,并发症较多,对化疗药物耐受性差,易产生毒副作用的特点,要加强对老年结核患者的认识,以及时总结达到早期诊断与治疗的目的。     

The effects of antipsychotic drug treatment on prolactin concentrations in elderly patients

OBJECTIVE: To describe the change in serum prolactin concentrations in elderly agitated nursing home patients with dementia who were newly initiated on olanzapine or switched to olanzapine treatment from either conventional antipsychotics or risperidone. METHODS: During an 8-week open-label olanzapine efficacy trial in elderly nursing home patients demonstrating clinically significant behavioral and psychological symptoms of dementia, serum prolactin concentrations were drawn on four occasions: at time of consent, following a washout period from previous therapy, midway through the study, and at endpoint. To assess post-hoc the effects of prolactin concentrations upon switching to olanzapine treatment, patients were divided into three different groups, based upon status at time of consent: those not taking antipsychotic medication, those taking any conventional antipsychotic, and those taking risperidone. Prolactin concentrations were assessed using a mixed-effect repeated-measures model. Symptom severity was measured using the Brief Psychiatric Rating Scale (BPRS), the Cohen-Mansfield Agitation Inventory (CMAI), the Clinical Global Impression (CGI)-Severity scale, and the Mini-Mental State Examination (MMSE), and the same repeated measures analysis was performed on these scales. RESULTS: Patients not on antipsychotic medication at study entry (29 females, 7 males) experienced a significant increase in prolactin concentration baseline to endpoint (P < 0.05) but remained below upper limit of normal for prolactin for both males and females. There was a nonsignificant increase in prolactin concentrations when patients were switched from conventional antipsychotic medications (mean dose 152.41 +/- 192.48 mg/day chlorpromazine equivalents) to olanzapine (2.5 to 10 mg/day) (22 females, 9 males). Patients who entered the study on risperidone (mean dose 1.31 +/- 0.91 mg/day) (13 females, 4 males) experienced a significant decrease in prolactin concentration (P < 0.001). While 62.5% of risperidone-treated patients had above-normal prolactin concentrations at baseline, only 21.4% had above-normal concentrations at endpoint (P = 0.033). Clear correlations between prolactin concentrations and clinical outcomes could not be determined. CONCLUSION: Consistent with previous findings in younger patients, olanzapine appeared to be a prolactin-sparing antipsychotic medication in the elderly with only modest prolactin increases observed. In addition, patients who were receiving risperidone and then switched to olanzapine experienced a significant reduction in prolactin concentrations that was sustained over the 8-week treatment course with olanzapine. One possible explanation for olanzapine's relatively modest increase in prolactin is that, unlike conventionals or risperidone, olanzapine binds less tightly with the dopamine D(2) receptor.     

头孢哌酮/舒巴坦治疗老年呼吸机相关性肺炎的临床分析

目的 观察头孢哌酮/舒巴坦治疗老年呼吸机相关性肺炎(VAP)的疗效与安全性.方法 回顾性分析2009年8月-2010年12月医院老年临床医学部呼吸内科诊断为VAP并接受头孢哌酮/舒巴坦治疗的老年患者临床资料.结果 40例老年VAP患者检出病原菌40株,主要为铜绿假单胞菌、肺炎克雷伯菌及大肠埃希菌,各分离出17、8、8株,分别占42.5％、20.0％、20.0％;40例患者中,痊愈11例、显效15例、进步10例、无效4例,总有效率为65.0％；治疗过程中未发现与头孢哌酮/舒巴坦有关的不良反应.结论 头孢哌酮/舒巴坦治疗老年VAP患者有效且安全.     

前列地尔脂微球载体制剂治疗老年不稳定性心绞痛临床观察

目的 观察前列地尔脂微球载体制剂(凯时)治疗老年不稳定性心绞痛(UA)的效果。方法 103例住院患者均 为男性,分为治疗组(凯时)64例和对照组(常规药物)39例。进行临床和实验室对比研究。结果 治疗组临床显效55例 (85.9％),有效6例(9.3％),无效3例(4.7％),总有效率95.3％。对照组39例,临床显效11例(28.2％),有效15例 (38.5％),无效13例(33.3％),总有效率66.7％。两组比较,有显著差异(P<0.001)。同时,血液流变学综合指标检查,治 疗组改善率93.7％(60/64)。对照组改善率79.4％(31/39)。治疗组与对照组比较有显著差异(P<0.01)。结论 前列地 尔对老年UA具有明显的治疗效果。